Related references
Note: Only part of the references are listed.EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion
Antonio Marzio et al.
CELL (2022)
Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer
Anthony J. Young et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Zhonglin Hao et al.
CLINICAL LUNG CANCER (2022)
Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP-a comparison of PARP imaging agents
Sophie Stotz et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
Lingying Wu et al.
GYNECOLOGIC ONCOLOGY (2021)
Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials
Chengyuan Wang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)
PARP inhibitors coming of age
Shani Paluch-Shimon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Repair of DNA Double-Strand Breaks by the Nonhomologous End Joining Pathway
Benjamin M. Stinson et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 90, 2021 (2021)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee et al.
LANCET ONCOLOGY (2021)
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition
Tom E. H. Ogden et al.
NUCLEIC ACIDS RESEARCH (2021)
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2021)
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
Kim A. Reiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors
Kasper Fugger et al.
SCIENCE (2021)
Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer
Monu Pandey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Repositioning PARP inhibitors in the treatment of thoracic malignancies
Francesco Passiglia et al.
CANCER TREATMENT REVIEWS (2021)
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2021)
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer
Vincenza Conteduca et al.
LANCET ONCOLOGY (2021)
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
Yiran Liang et al.
SEMINARS IN CANCER BIOLOGY (2020)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks et al.
ANNALS OF ONCOLOGY (2020)
PARP and PARG inhibitors in cancer treatment
Dea Slade
GENES & DEVELOPMENT (2020)
HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation
Marcin J. Suskiewicz et al.
NATURE (2020)
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication
Madalena Tarsounas et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann et al.
LANCET ONCOLOGY (2020)
Biomarker-Guided Development of DNA Repair Inhibitors
James M. Cleary et al.
MOLECULAR CELL (2020)
Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer A Nonrandomized Clinical Trial
Elizabeth S. McDonald et al.
JAMA ONCOLOGY (2020)
An update on the immune landscape in lung and head and neck cancers
Jennifer W. Carlisle et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial
Laurie E. Steffen McLouth et al.
CANCER MEDICINE (2020)
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
Francesco Paolo Fiorentino et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M. Chabanon et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins
Elizaveta E. Alemasova et al.
NUCLEIC ACIDS RESEARCH (2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging therapies for small cell lung cancer
Sen Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Unexpected Synergy Reveals New Therapeutic Strategy in SCLC
Benjamin J. Drapkin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang et al.
CANCER CELL (2019)
Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts
James Laird et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
Carl M. Gay et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
A. Pavan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors
Florence Atrafi et al.
CLINICAL CANCER RESEARCH (2019)
Prospects of targeted and immune therapies in SCLC
Lizza E. L. Hendriks et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Circular RNA circNOL10 Inhibits Lung Cancer Development by Promoting SCLM1-Mediated Transcriptional Regulation of the Humanin Polypeptide Family
Aruo Nan et al.
ADVANCED SCIENCE (2019)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
Alice Lallo et al.
CLINICAL CANCER RESEARCH (2018)
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
James H. Laird et al.
CLINICAL CANCER RESEARCH (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Precision oncology in non-small-cell lung cancer : opportunities and challenges
Chul Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
Kristen E. Clements et al.
NUCLEIC ACIDS RESEARCH (2018)
NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains
Marie-France Langelier et al.
NATURE COMMUNICATIONS (2018)
Target engagement imaging of PARP inhibitors in small-cell lung cancer
Brandon Carney et al.
NATURE COMMUNICATIONS (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
PTEN: Tumor Suppressor and Metabolic Regulator
Chien-Yu Chen et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity
Benjamin J. Drapkin et al.
CANCER RESEARCH (2018)
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
Brittany Haynes et al.
CANCER TREATMENT REVIEWS (2018)
Talazoparib for BRCA-mutated advanced breast cancer
Ashray Gunjur
LANCET ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preliminary evaluation of a novel F-18-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer
Dong Zhou et al.
NUCLEAR MEDICINE AND BIOLOGY (2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson et al.
BRITISH JOURNAL OF CANCER (2018)
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E. Wahner Hendrickson et al.
CLINICAL CANCER RESEARCH (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Molecular Imaging of PARP
Brandon Carney et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
Alberto Ballestrero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
PARP inhibitors for targeted treatment in ovarian cancer
Don S. Dizon
LANCET (2017)
Olaparib provides benefit in metastatic breast cancer
Manjulika Das
LANCET ONCOLOGY (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Treatment advances in small cell lung cancer (SCLC)
Saiama N. Waqar et al.
PHARMACOLOGY & THERAPEUTICS (2017)
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies
Loren S. Michel et al.
RADIOLOGY (2017)
DNA-PKcs structure suggests an allosteric mechanism modulating DNA double-strand break repair
Bancinyane L. Sibanda et al.
SCIENCE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
Jian xin Zhou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent
Beverly A. Teicher et al.
CANCER MEDICINE (2017)
Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.
Taofeek Kunle Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
Mallika S. Dhawan et al.
CLINICAL CANCER RESEARCH (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Yanhua Mu et al.
EMBO REPORTS (2016)
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models
Brandon Carney et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Mehran Makvandi et al.
CANCER RESEARCH (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers
Petra Schwertman et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
Robert J. Cardnell et al.
PLOS ONE (2016)
Origins, genetic landscape, and emerging therapies of small cell lung cancer
Ekaterina A. Semenova et al.
GENES & DEVELOPMENT (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo
Filip Zmuda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
Taofeek K. Owonikoko et al.
LUNG CANCER (2015)
PARPs and ADP-Ribosylation: 50 Years ... and Counting
W. Lee Kraus
MOLECULAR CELL (2015)
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma
Giuseppe Carlucci et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
7Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Maria Teresa Esposito et al.
NATURE MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer
Jamin D. Steffen et al.
CANCER RESEARCH (2014)
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K. Owonikoko et al.
CANCER MEDICINE (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell et al.
CLINICAL CANCER RESEARCH (2013)
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Nicola J. Curtin et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Poly-ADP-ribose polymerase: Machinery for nuclear processes
Colin Thomas et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Mechanisms of Resistance to PARP Inhibitors-Three and Counting
Tito Fojo et al.
CANCER DISCOVERY (2013)
Management of Small Cell Lung Cancer
Raffaele Califano et al.
DRUGS (2012)
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Elisabet Wahlberg et al.
NATURE BIOTECHNOLOGY (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus
Wenjian Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
A Genetic Snapshot of Small Cell Lung Cancer
Rafael Rosell et al.
CANCER DISCOVERY (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
High-Yielding, Two-Step 18F Labeling Strategy for 18F-PARP1 Inhibitors
Edmund J. Keliher et al.
CHEMMEDCHEM (2011)
Surgery for Early-Stage Small Cell Lung Cancer
Bryan J. Schneider et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Treatment options for small cell lung cancer - do we have more choice?
M. Puglisi et al.
BRITISH JOURNAL OF CANCER (2010)
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini et al.
CLINICAL CANCER RESEARCH (2010)
Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance
David Engelmann et al.
DRUG RESISTANCE UPDATES (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Joann P. Palma et al.
CLINICAL CANCER RESEARCH (2009)
Targeting the DNA damage response for cancer therapy
Simon N. Powell et al.
DNA REPAIR (2009)
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Kazuto Sugimura et al.
JOURNAL OF CELL BIOLOGY (2008)
PARP inhibition versus PARP-1 silencing:: different outcomes in terms of single-strand break repair and radiation susceptibility
Camille Godon et al.
NUCLEIC ACIDS RESEARCH (2008)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The DNA damage response, immunity and cancer
Stephan Gasser et al.
SEMINARS IN CANCER BIOLOGY (2006)
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial
AM Moore et al.
LUNG CANCER (2006)
Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells
H Hochegger et al.
EMBO JOURNAL (2006)
Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis
ZD Tu et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
P Jagtap et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Share Paper
